Platinum Investment Management Ltd. Sells 344,613 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Platinum Investment Management Ltd. lessened its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 9.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,180,295 shares of the company's stock after selling 344,613 shares during the period. Platinum Investment Management Ltd. owned 1.40% of Gossamer Bio worth $2,877,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Monaco Asset Management SAM lifted its holdings in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after buying an additional 1,520,721 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after acquiring an additional 13,902 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company's stock valued at $1,862,000 after purchasing an additional 442,895 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Gossamer Bio by 24.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company's stock worth $380,000 after purchasing an additional 74,920 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the 3rd quarter worth approximately $67,000. 81.23% of the stock is currently owned by institutional investors.

Remove Ads

Gossamer Bio Stock Up 3.0 %

Shares of GOSS traded up $0.04 during trading hours on Friday, reaching $1.39. The company's stock had a trading volume of 1,068,430 shares, compared to its average volume of 1,566,248. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a market cap of $315.84 million, a price-to-earnings ratio of -4.34 and a beta of 1.86. The company has a 50 day moving average of $1.16 and a two-hundred day moving average of $0.98. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million. As a group, research analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on GOSS shares. Wedbush restated an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a report on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Gossamer Bio in a research report on Tuesday, March 18th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $9.20.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.